Clinical Decision Simulator

This program is supported by an independent education grant from Lilly. This education program has been designed for healthcare professionals globally, excluding the UK.

Target Audience

This activity is intended for rheumatologists who care for patients with psoriatic arthritis (PsA).

Faculty

Prof. Peter Korsten

Prof. Peter Korsten is Chief of the Department of Rheumatology and Clinical Immunology at St. Josef-Stift Sendenhorst, Germany. His research focuses on outcomes in rheumatology, with particular expertise in rare systemic autoimmune diseases, including sarcoidosis, systemic lupus erythematosus, myositis, and systemic sclerosis, as well as musculoskeletal ultrasound.

Learning objectives

After completing this activity, the participant should be better able to:
1. Recognize the obesity-inflammation axis as a treatment-relevant inflammatory and disease modifier in PsA, including its impact on disease activity and treatment response, to inform clinical reasoning and comprehensive interpretation of disease activity, in ≥80% of case-based assessment scenarios.

2. Apply individualized treatment strategies that systematically incorporate obesity and metabolic factors when evaluating disease activity (including emerging evidence on the co-management of weight-loss therapies) in people with PsA to optimize joint and systemic control whilst managing adverse events, in ≥75% of clinical decision scenarios.

3. Apply patient-centred communication strategies to initiate and integrate weight management discussions into PsA care, including setting realistic expectations for concurrent joint and metabolic improvements and supporting shared decision-making, in ≥70% of simulated clinical interactions.

4. Integrate weight management into PsA care pathways by identifying appropriate patients and facilitating timely treatment, referral or shared care with obesity specialists—including building confidence in co-managing modern systemic anti-obesity therapies—to support coordinated, multidisciplinary management and improve outcomes, in ≥70% of pathway-based clinical scenarios.

This continuing education activity is available from 31st August 2026 and will expire 14th June 2027

Estimated time to complete this activity: 15 minutes